J. Couzin-frankel, Breakthrough of the year 2013, Cancer immunotherapy. Science, vol.342, pp.1432-1435, 2013.

D. S. Chen and I. Mellman, Oncology meets immunology: the cancer-immunity cycle, Immunity, vol.39, pp.1-10, 2013.

Y. Yang, Cancer immunotherapy: harnessing the immune system to battle cancer, J Clin Invest, vol.125, pp.3335-3342, 2015.

J. C. Hassel, Ipilimumab plus nivolumab for advanced melanoma, Lancet Oncol, vol.17, pp.1471-1473, 2016.

R. D. Schreiber, L. J. Old, and M. J. Smyth, Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion, Science, vol.331, pp.1565-70, 2011.

L. Zitvogel, L. Galluzzi, M. J. Smyth, and G. Kroemer, Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance, Immunity, vol.39, pp.74-88, 2013.

K. Kersten, C. Salvagno, and K. E. De-visser, Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy, Front Immunol, vol.6, p.516, 2015.

M. Laplante and D. M. Sabatini, mTOR signaling in growth control and disease, Cell, vol.149, pp.274-93, 2012.

R. J. Shaw, L. C. Cantley, and . Ras, PI(3)K and mTOR signalling controls tumour cell growth, Nature, vol.441, pp.424-454, 2006.

G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin et al., Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma, N Engl J Med, vol.356, pp.2271-81, 2007.

R. J. Motzer, B. Escudier, S. Oudard, T. E. Hutson, C. Porta et al., Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebocontrolled phase III trial, Lancet, vol.372, pp.449-56, 2008.

J. Baselga, M. Campone, M. Piccart, H. A. Burris, H. S. Rugo et al., Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer, N Engl J Med, vol.366, pp.520-529, 2012.

L. Beziaud, L. Mansi, P. Ravel, M. El, C. Laheurte et al., Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity, Cancer Res, vol.76, pp.4100-4112, 2016.

A. Thiery-vuillemin, C. Laheurte, L. Mansi, B. Royer, X. Pivot et al., Immunomodulatory effects of everolimus in a long responsive patient with metastatic renal cell carcinoma, J Immunother, vol.37, pp.51-55, 2014.

H. Chi, Regulation and function of mTOR signalling in T cell fate decisions, Nat Rev Immunol, vol.12, pp.325-363, 2012.

K. Araki, A. P. Turner, V. O. Shaffer, S. Gangappa, S. A. Keller et al., mTOR regulates memory CD8 T-cell differentiation, Nature, vol.460, pp.108-120, 2009.

Q. Li, R. R. Rao, K. Araki, K. Pollizzi, K. Odunsi et al., A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity, Immunity, vol.34, pp.541-53, 2011.

R. R. Rao, Q. Li, K. Odunsi, and P. A. Shrikant, The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin, Immunity, vol.32, pp.67-78, 2010.

L. Zhang, B. O. Tschumi, I. C. Lopez-mejia, S. G. Oberle, M. Meyer et al., Mammalian Target of Rapamycin Complex 2 Controls CD8 T Cell Memory Differentiation in a Foxo1-Dependent Manner, Cell Rep, vol.14, pp.1206-1223, 2016.

E. Amiel, B. Everts, T. C. Freitas, I. L. King, J. D. Curtis et al., Inhibition of Mechanistic Target of Rapamycin Promotes Dendritic Cell Activation and Enhances Therapeutic Autologous Vaccination in Mice, J Immunol, vol.189, pp.2151-2159, 2012.

M. Diken, S. Kreiter, F. Vascotto, A. Selmi, S. Attig et al., mTOR inhibition improves antitumor effects of vaccination with antigen-encoding RNA, Cancer Immunol Res, vol.1, pp.386-92, 2013.

N. Chaoul, C. Fayolle, B. Desrues, M. Oberkampf, A. Tang et al., Rapamycin Impairs Antitumor CD8+ T-cell Responses and Vaccine-Induced Tumor Eradication, Cancer Res, vol.75, pp.3279-91, 2015.
URL : https://hal.archives-ouvertes.fr/pasteur-01291982

Y. Wang, X. Wang, J. R. Subjeck, P. A. Shrikant, and H. L. Kim, Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines, Br J Cancer, vol.104, pp.643-52, 2011.

Y. Wang, T. Sparwasser, R. Figlin, and H. L. Kim, Foxp3+ T cells inhibit antitumor immune memory modulated by mTOR inhibition, Cancer Res, vol.74, pp.2217-2245, 2014.

M. Battaglia, A. Stabilini, and M. Roncarolo, Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells, Blood, vol.105, pp.4743-4751, 2005.

M. Noris, F. Casiraghi, M. Todeschini, P. Cravedi, D. Cugini et al., Regulatory T cells and T cell depletion: role of immunosuppressive drugs, J Am Soc Nephrol JASN, vol.18, pp.1007-1025, 2007.

G. M. Delgoffe, T. P. Kole, Y. Zheng, P. E. Zarek, K. L. Matthews et al., The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment, Immunity, vol.30, pp.832-876, 2009.

G. M. Delgoffe, K. N. Pollizzi, A. T. Waickman, E. Heikamp, D. J. Meyers et al., The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2, Nat Immunol, vol.12, pp.295-303, 2011.

A. Iellem, M. Mariani, R. Lang, H. Recalde, P. Panina-bordignon et al., Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells, J Exp Med, vol.194, pp.847-53, 2001.

K. Lahl, C. Loddenkemper, C. Drouin, J. Freyer, J. Arnason et al., Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease, J Exp Med, vol.204, pp.57-63, 2007.
URL : https://hal.archives-ouvertes.fr/pasteur-00161238

M. Laplante and D. M. Sabatini, mTOR signaling in growth control and disease, Cell, vol.149, pp.274-293, 2012.

S. Xie, Identification of a role for the PI3K/AKT/mTOR signaling pathway in innate immune cells, PloS One, vol.9, p.94496, 2014.

K. Araki, B. Youngblood, and R. Ahmed, The role of mTOR in memory CD8 T-cell differentiation, Immunol. Rev, vol.235, pp.234-243, 2010.

K. Araki, mTOR regulates memory CD8 T-cell differentiation, Nature, vol.460, pp.108-112, 2009.

G. M. Delgoffe, The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment, Immunity, vol.30, pp.832-844, 2009.

J. D. Powell and G. M. Delgoffe, The mammalian Target of Rapamycin (mTOR) provides a critical link between T cell differentiation, function and metabolism, Immunity, vol.33, pp.301-311, 2010.

H. Chi, Regulation and function of mTOR signalling in T cell fate decisions, Nat. Rev. Immunol, vol.12, pp.325-338, 2012.

R. G. Jones and E. J. Pearce, MenTORing Immunity: mTOR Signaling in the Development and Function of Tissue-Resident Immune Cells, Immunity, vol.46, pp.730-742, 2017.

R. J. Shaw, L. C. Cantley, and . Ras, PI(3)K and mTOR signalling controls tumour cell growth, Nature, vol.441, pp.424-430, 2006.

F. Chiarini, C. Evangelisti, J. A. Mccubrey, and A. M. Martelli, Current treatment strategies for inhibiting mTOR in cancer, Trends Pharmacol. Sci, vol.36, pp.124-135, 2015.

S. Faes, N. Demartines, and O. Dormond, Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity, Oxid. Med. Cell. Longev, vol.2017, p.1726078, 2017.

J. A. Mccubrey, Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response, Oncotarget, vol.3, pp.954-987, 2012.

N. Wagle, Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib, Cancer Discov, vol.4, pp.546-553, 2014.

B. C. Grabiner, A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity, Cancer Discov, vol.4, pp.554-563, 2014.

L. C. Kim, R. S. Cook, and J. Chen, mTORC1 and mTORC2 in cancer and the tumor microenvironment, Oncogene, vol.36, pp.2191-2201, 2017.

C. Porta, C. Paglino, and A. Mosca, Targeting PI3K/Akt/mTOR Signaling in Cancer, Front. Oncol, vol.4, 2014.

J. Xie, X. Wang, and C. G. Proud, mTOR inhibitors in cancer therapy, vol.5, p.2078, 2016.

M. Guba, Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor, Nat. Med, vol.8, pp.128-135, 2002.

W. Jacobsen, Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD, Transplant. Proc, vol.33, pp.514-515, 2001.

T. F. Cloughesy, Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTENdeficient glioblastoma, PLoS Med, vol.5, p.8, 2008.

D. Benjamin, M. Colombi, C. Moroni, and M. N. Hall, Rapamycin passes the torch: a new generation of mTOR inhibitors, Nat. Rev. Drug Discov, vol.10, pp.868-880, 2011.

G. Hudes, Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma, N. Engl. J. Med, vol.356, pp.2271-2281, 2007.

G. Hess, Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.27, pp.3822-3829, 2009.

M. E. Pavel, Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study, Lancet Lond. Engl, vol.378, 2005.

J. C. Yao, Everolimus for advanced pancreatic neuroendocrine tumors, N. Engl. J. Med, vol.364, pp.514-523, 2011.

R. J. Motzer, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial, Lancet, vol.372, pp.449-456, 2008.

J. Baselga, Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer, N. Engl. J. Med, vol.366, pp.520-529, 2012.

N. Pallet and C. Legendre, Adverse events associated with mTOR inhibitors, Expert Opin. Drug Saf, vol.12, pp.177-186, 2013.

K. Sadowski, K. Kotulska, and S. Jó?wiak, Management of side effects of mTOR inhibitors in tuberous sclerosis patients, Pharmacol. Rep. PR, vol.68, pp.536-542, 2016.

A. Thiery-vuillemin, Immunomodulatory effects of everolimus in a long responsive patient with metastatic renal cell carcinoma, J. Immunother. Hagerstown Md, vol.37, pp.51-54, 1997.

J. Dancey, mTOR signaling and drug development in cancer, Nat. Rev. Clin. Oncol, vol.7, pp.209-219, 2010.

A. Kornakiewicz, Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma, Curr. Signal Transduct. Ther, vol.8, pp.210-218, 2014.

J. Bertacchini, Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis, Leukemia, vol.28, pp.2197-2205, 2014.

A. Efeyan and D. M. Sabatini, mTOR and cancer: many loops in one pathway, Curr. Opin. Cell Biol, vol.22, pp.169-176, 2010.

D. A. Gewirtz, The four faces of autophagy: implications for cancer therapy, Cancer Res, vol.74, pp.647-651, 2014.

R. E. Brown, Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: Pathogenesis and therapeutic options, Oncotarget, vol.7, pp.41612-41621, 2016.

S. Maira, Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity, Mol. Cancer Ther, vol.7, pp.1851-1863, 2008.

S. D. Knight, Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin, ACS Med. Chem. Lett, vol.1, pp.39-43, 2010.

P. Yu, Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway, Mol. Cancer Ther, vol.13, pp.1078-1091, 2014.

J. A. Engelman, Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers, Nat. Med, vol.14, pp.1351-1356, 2008.

T. M. Wise-draper, A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies, Target. Oncol, 2017.

A. C. Hsieh, Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E, Cancer Cell, vol.17, pp.249-261, 2010.

C. M. Chresta, AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity, Cancer Res, vol.70, pp.288-298, 2010.

N. Carayol, Critical roles for mTORC2-and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells, Proc. Natl. Acad. Sci. U. S. A, vol.107, pp.12469-12474, 2010.

V. S. Rodrik-outmezguine, Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor, Nature, vol.534, pp.272-276, 2016.

Q. Fan, A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma, Cancer Cell, vol.31, pp.424-435, 2017.

M. Hidalgo, A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.12, pp.5755-5763, 2006.

M. M. Mita, Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.26, pp.361-367, 2008.

C. Fiorini, Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors, Am. J. Cancer Res, vol.4, pp.907-915, 2014.

M. Laplante and D. M. Sabatini, Regulation of mTORC1 and its impact on gene expression at a glance, J. Cell Sci, vol.126, pp.1713-1719, 2013.

V. P. Krymskaya and E. Goncharova, A. PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects, Cell Cycle Georget. Tex, vol.8, pp.403-413, 2009.

M. H. Voss, Tumor genomic analysis for 128 renal cell carcinoma (RCC) patients receiving firstline everolimus: Correlation between outcome and mutations status in MTOR, TSC1, and TSC2, J. Clin. Oncol, vol.35, 2017.

K. Araki, A. H. Ellebedy, and R. Ahmed, TOR in the immune system, Curr. Opin. Cell Biol, vol.23, pp.707-715, 2011.

G. M. Delgoffe, The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2, Nat. Immunol, vol.12, pp.295-303, 2011.

A. Sakata, K. Kuwahara, T. Ohmura, S. Inui, and N. Sakaguchi, Involvement of a rapamycin-sensitive pathway in CD40-mediated activation of murine B cells in vitro, Immunol. Lett, vol.68, pp.301-309, 1999.

A. C. Donahue and D. A. Fruman, Distinct signaling mechanisms activate the target of rapamycin in response to different B-cell stimuli, Eur. J. Immunol, vol.37, pp.2923-2936, 2007.

E. Amiel, Inhibition of mechanistic target of rapamycin promotes dendritic cell activation and enhances therapeutic autologous vaccination in mice, J. Immunol. Baltim. Md, vol.189, pp.2151-2158, 1950.

M. Ohtani, Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells, Blood, vol.112, pp.635-643, 2008.

H. R. Turnquist, mTOR and GSK-3 shape the CD4+ T-cell stimulatory and differentiation capacity of myeloid DCs after exposure to LPS, Blood, vol.115, pp.4758-4769, 2010.

T. Weichhart, The TSC-mTOR signaling pathway regulates the innate inflammatory response, Immunity, vol.29, pp.565-577, 2008.

C. Zhang, The mTOR signal regulates myeloid-derived suppressor cells differentiation and immunosuppressive function in acute kidney injury, Cell Death Dis, vol.8, p.2695, 2017.

K. Makki, Beneficial metabolic effects of rapamycin are associated with enhanced regulatory cells in diet-induced obese mice, PloS One, vol.9, p.92684, 2014.

T. Nakamura, T. Nakao, N. Yoshimura, and E. Ashihara, Rapamycin Prolongs Cardiac Allograft Survival in a Mouse Model by Inducing Myeloid-Derived Suppressor Cells, Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg, 2015.

R. P. Donnelly, mTORC1-dependent metabolic reprogramming is a prerequisite for NK cell effector function, J. Immunol. Baltim. Md, pp.4477-4484, 2014.

A. Marçais and T. Walzer, mTOR: a gate to NK cell maturation and activation, Cell Cycle Georget. Tex, vol.13, pp.3315-3316, 2014.

R. Keating, M. A. Mcgargill, and . Mtor, Regulation of Lymphoid Cells in Immunity to Pathogens. Front. Immunol, vol.7, 2016.

J. Wei, K. Yang, and H. Chi, Cutting edge: Discrete functions of mTOR signaling in invariant NKT cell development and NKT17 fate decision, J. Immunol. Baltim. Md, pp.4297-4301, 2014.

H. Li and C. D. Pauza, Rapamycin increases the yield and effector function of human ?? T cells stimulated in vitro, Cancer Immunol. Immunother. CII, vol.60, pp.361-370, 2011.

A. P. Turner, Sirolimus enhances the magnitude and quality of viral-specific CD8+ T-cell responses to vaccinia virus vaccination in rhesus macaques, Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg, vol.11, pp.613-618, 2011.

R. R. Rao, Q. Li, K. Odunsi, and P. A. Shrikant, The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin, Immunity, vol.32, pp.67-78, 2010.

Q. Li, A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity, Immunity, vol.34, pp.541-553, 2011.

G. Scholz, Modulation of mTOR Signalling Triggers the Formation of Stem Cell-like, Memory T Cells. EBioMedicine, vol.4, pp.50-61, 2016.

L. Beziaud, Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity, Cancer Res, vol.76, pp.4100-4112, 2016.

H. Zeng, mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function, Nature, vol.499, pp.485-490, 2013.

M. Battaglia, A. Stabilini, and M. Roncarolo, Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells, Blood, vol.105, pp.4743-4748, 2005.

S. Sauer, T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR, Proc. Natl. Acad. Sci. U. S. A, vol.105, pp.7797-7802, 2008.

S. Haxhinasto, D. Mathis, and C. Benoist, The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells, J. Exp. Med, vol.205, pp.565-574, 2008.

T. K. Hendrikx, Monotherapy rapamycin allows an increase of CD4 CD25 FoxP3 T cells in renal recipients, Transpl. Int. Off. J. Eur. Soc. Organ Transplant, vol.22, pp.884-891, 2009.

M. Noris, Regulatory T Cells and T Cell Depletion: Role of Immunosuppressive Drugs, J. Am. Soc. Nephrol, vol.18, pp.1007-1018, 2007.

M. Sabbatini, Oscillatory mTOR inhibition and Treg increase in kidney transplantation, Clin. Exp. Immunol, vol.182, pp.230-240, 2015.

L. Vallotton, Monitoring of CD4+CD25highIL-7R?high activated T cells in kidney transplant recipients, Clin. J. Am. Soc. Nephrol. CJASN, vol.6, pp.2025-2033, 2011.

L. Lu, Rapamycin promotes the expansion of CD4(+) Foxp3(+) regulatory T cells after liver transplantation, Transplant. Proc, vol.42, pp.1755-1757, 2010.

H. Shin, Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells, Blood, vol.118, pp.2342-2350, 2011.

X. Wang, W. Wang, J. Xu, and Q. Le, Effect of rapamycin and interleukin-2 on regulatory

, CD4+CD25+Foxp3+ T cells in mice after allogenic corneal transplantation, Transplant. Proc, vol.45, pp.528-537, 2013.

J. E. Foley, Ex vivo rapamycin generates donor Th2 cells that potently inhibit graft-versus-host disease and graft-versus-tumor effects via an IL-4-dependent mechanism, J. Immunol. Baltim. Md, vol.175, pp.5732-5743, 1950.

U. Jung, Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy, Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant, vol.12, pp.905-918, 2006.

J. Mariotti, Ex vivo rapamycin generates apoptosis-resistant donor Th2 cells that persist in vivo and prevent hemopoietic stem cell graft rejection, J. Immunol. Baltim. Md, vol.180, pp.89-105, 1950.

S. Amarnath, Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD, Autophagy, vol.6, pp.523-541, 2010.

E. Crespo, Effector Antitumor and Regulatory T Cell Responses Influence the Development of Nonmelanoma Skin Cancer in Kidney Transplant Patients, Transplantation, 2017.

J. Jung, Does the nature of residual immune function explain the differential risk of nonmelanoma skin cancer development in immunosuppressed organ transplant recipients?, Int. J. Cancer, vol.138, pp.281-292, 2016.

A. J. Templeton, Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08), Eur. Urol, vol.64, pp.150-158, 2013.

M. Kobayashi, Changes in peripheral blood immune cells: their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapy, Med. Oncol. Northwood Lond. Engl, vol.30, p.556, 2013.

C. Laheurte, Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4(+) Th1 responses against telomerase in cancer patients, Oncoimmunology, vol.5, p.1137416, 2016.

O. Adotevi, A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients, J. Immunother. Hagerstown Md, vol.33, pp.991-998, 1997.

M. H. Voss, Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, 2016.

A. Ravaud, RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon ?-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol, vol.26, pp.1378-1384, 2015.

D. Koeberle, Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29), Ann. Oncol. Off. J. Eur. Soc. Med. Oncol, vol.27, pp.856-861, 2016.

R. Kanesvaran, A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma, Clin. Genitourin. Cancer, vol.13, pp.319-327, 2015.

F. Ghiringhelli, Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+

, regulatory T cells and restores T and NK effector functions in end stage cancer patients, Cancer Immunol. Immunother. CII, vol.56, pp.641-648, 2007.

T. J. Curiel, Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival, Nat. Med, vol.10, pp.942-949, 2004.

J. Bayry, E. Tartour, and D. F. Tough, Targeting CCR4 as an emerging strategy for cancer therapy and vaccines, Trends Pharmacol. Sci, vol.35, pp.163-165, 2014.

J. Bayry, In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination, Proc. Natl. Acad. Sci. U. S. A, vol.105, pp.10221-10226, 2008.

W. Peng, Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy, Cancer Discov, vol.6, pp.202-216, 2016.

R. J. Motzer, Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma, N. Engl. J. Med, vol.373, pp.1803-1813, 2015.

T. K. Choueiri, Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.22, pp.5461-5471, 2016.

L. Zitvogel, L. Galluzzi, M. J. Smyth, and G. Kroemer, Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance, Immunity, vol.39, pp.74-88, 2013.

L. Galluzzi, Classification of current anticancer immunotherapies, Oncotarget, vol.5, pp.12472-12508, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-01142463

R. Kennedy and E. Celis, Multiple roles for CD4+ T cells in anti-tumor immune responses, Immunol. Rev, vol.222, pp.129-144, 2008.

S. Ostrand-rosenberg, CD4+ T lymphocytes: a critical component of antitumor immunity, Cancer Invest, vol.23, pp.413-419, 2005.

M. J. Bevan, Helping the CD8(+) T-cell response, Nat. Rev. Immunol, vol.4, pp.595-602, 2004.

D. J. Shedlock and H. Shen, Requirement for CD4 T cell help in generating functional CD8 T cell memory, Science, vol.300, pp.337-339, 2003.

A. Perez-diez, CD4 cells can be more efficient at tumor rejection than CD8 cells, Blood, vol.109, pp.5346-5354, 2007.

R. Bos and L. A. Sherman, CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes, Cancer Res, vol.70, pp.8368-8377, 2010.

Y. Nakanishi, B. Lu, C. Gerard, and A. Iwasaki, CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help, Nature, vol.462, pp.510-513, 2009.

W. H. Fridman, F. Pagès, C. Sautès-fridman, and J. Galon, The immune contexture in human tumours: impact on clinical outcome, Nat. Rev. Cancer, vol.12, pp.298-306, 2012.

K. M. Aagaard-tillery and D. F. Jelinek, « Inhibition of Human B Lymphocyte Cell Cycle Progression and Differentiation by Rapamycin, Cellular Immunology, vol.156, issue.2, pp.493-507, 1994.

O. Adotévi, M. Dosset, J. Galaine, L. Beziaud, Y. Godet et al., « Targeting Antitumor CD4 Helper T Cells with Universal Tumor-Reactive Helper Peptides Derived from Telomerase for Cancer Vaccine, Human Vaccines & Immunotherapeutics, vol.9, issue.5, pp.1073-77, 2013.

O. Adotevi, H. Pere, P. Ravel, N. Haicheur, C. Badoual et al., « A Decrease of Regulatory T Cells Correlates with Overall Survival after Sunitinib-Based Antiangiogenic Therapy in Metastatic Renal Cancer Patients », Journal of Immunotherapy, vol.33, issue.9, pp.991-98, 1997.

O. Adotevi, B. Vingert, L. Freyburger, P. Shrikant, Y. Lone et al., « B Subunit of Shiga ToxinBased Vaccines Synergize with Alpha-Galactosylceramide to Break Tolerance against Self Antigen and Elicit Antiviral Immunity », Journal of Immunology, vol.179, issue.5, pp.3371-79, 1950.

J. Alberú, M. D. Pascoe, J. M. Campistol, F. P. Schena, M. D. et al., « Lower Malignancy Rates in Renal Allograft Recipients Converted to Sirolimus-Based, Calcineurin Inhibitor-Free Immunotherapy: 24-Month Results from the CONVERT Trial, Transplantation, vol.92, issue.3, pp.303-313, 2011.

A. Ali, N. Kassim, . Nandagopal, S. Et, and . Lee, « IL-15-PI3K-AKT-MTOR: A Critical Pathway in the Life Journey of Natural Killer Cells, vol.6, p.355, 2015.

E. Amiel, B. Everts, T. C. Freitas, I. L. King, J. D. Curtis et al., « Inhibition of Mechanistic Target of Rapamycin Promotes Dendritic Cell Activation and Enhances Therapeutic Autologous Vaccination in Mice », Journal of Immunology, vol.189, issue.5, pp.2151-58, 1950.

D. Appalla, A. Depalma, S. Et, and . Calderwood, « Mammalian Target of Rapamycin Inhibitor Induced Complete Remission of a Recurrent Subependymal Giant Cell Astrocytoma in a Patient Without Features of Tuberous Sclerosis Complex, Pediatric Blood & Cancer, vol.63, issue.7, pp.1276-78, 2016.

. Araki, A. P. Koichi, V. O. Turner, S. Shaffer, S. A. Gangappa et al., MTOR Regulates Memory CD8 T-Cell Differentiation, vol.460, pp.108-120, 2009.

K. Araki, B. Youngblood, R. Et, and . Ahmed, The Role of MTOR in Memory CD8 TCell Differentiation, vol.235, pp.234-277, 2010.

J. Baselga, M. Campone, M. Piccart, H. A. Burris, H. S. Rugo et al., Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer, vol.366, pp.520-549, 2012.

S. Basu, T. Golovina, T. Mikheeva, C. H. June, and J. L. Riley, « Cutting Edge: Foxp3-Mediated Induction of Pim 2 Allows Human T Regulatory Cells to Preferentially Expand in Rapamycin », Journal of Immunology, vol.180, issue.9, pp.5794-98, 1950.

M. Battaglia, A. Stabilini, B. Migliavacca, J. Horejs-hoeck, T. Kaupper et al., « Rapamycin Promotes Expansion of Functional CD4+CD25+FOXP3+ Regulatory T Cells of Both Healthy Subjects and Type 1 Diabetic Patients », Journal of Immunology, vol.177, issue.12, pp.8338-8385, 1950.

M. Battaglia, A. Stabilini, M. Et, and . Roncarolo, Rapamycin Selectively Expands CD4+CD25+FoxP3+ Regulatory T Cells, vol.105, pp.4743-4791, 2005.

J. Bayry, E. Tartour, D. F. Et, and . Tough, « Targeting CCR4 as an Emerging Strategy for Cancer Therapy and Vaccines », Trends in Pharmacological Sciences, vol.35, issue.4, pp.163-65, 2014.

E. Becht, N. A. Giraldo, B. Beuselinck, S. Job, L. Marisa et al., Prognostic and Theranostic Impact of Molecular Subtypes and Immune Classifications in Renal Cell Cancer (RCC) and Colorectal Cancer (CRC), Oncoimmunology, vol.4, issue.12, p.1049804, 2015.

E. Becht, N. A. Giraldo, C. Germain, A. De-reyniès, P. Laurent-puig et al., « Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers, Advances in Immunology, vol.130, pp.95-190, 2016.

S. Benhamron, B. Et, and . Tirosh, « Direct Activation of MTOR in B Lymphocytes Confers Impairment in B-Cell Maturation Andloss of Marginal Zone B Cells, European Journal of Immunology, vol.41, issue.8, pp.2390-96, 2011.

D. Benjamin, M. Colombi, C. Moroni, M. N. Et, and . Hall, Rapamycin Passes the Torch: A New Generation of MTOR Inhibitors, vol.10, pp.868-80, 2011.

J. Bertacchini, M. Guida, B. Accordi, L. Mediani, A. M. Martelli et al., « Feedbacks and Adaptive Capabilities of the PI3K/Akt/MTOR Axis in Acute Myeloid Leukemia Revealed by Pathway Selective Inhibition and Phosphoproteome Analysis, Leukemia, vol.28, issue.11, pp.2197-2205, 2014.

. Beuselinck, S. Benoit, E. Job, A. Becht, V. Karadimou et al., « Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol.21, issue.6, pp.1329-1368, 2015.

A. M. Bilate, J. J. Et, and . Lafaille, « Induced CD4+Foxp3+ Regulatory T Cells in Immune Tolerance, Annual Review of Immunology, vol.30, pp.733-58, 2012.

G. Bindea, B. Mlecnik, M. Tosolini, A. Kirilovsky, M. Waldner et al., « Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer, Immunity, vol.39, issue.4, pp.782-95, 2013.

K. Bocian, J. Borysowski, P. Wierzbicki, J. Wyzgal, D. Klosowska et al., Rapamycin, Unlike Cyclosporine A, Enhances Suppressive Functions of in VitroInduced CD4+CD25+ Tregs ». Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association, vol.25, pp.710-727, 2010.

R. Bos, A. Linda, and . Sherman, « CD4+ T-Cell Help in the Tumor Milieu Is Required for Recruitment and Cytolytic Function of CD8+ T Lymphocytes, Cancer Research, vol.70, issue.21, pp.8368-77, 2010.

C. Bourgeois, B. Rocha, C. Et, and . Tanchot, A Role for CD40 Expression on CD8+ T Cells in the Generation of CD8+ T Cell Memory ». Science, vol.297, pp.2060-63, 2002.

S. Brouard, I. Puig-pey, J. Lozano, A. Pallier, C. Braud et al., « Comparative Transcriptional and Phenotypic Peripheral Blood Analysis of Kidney Recipients under Cyclosporin A or Sirolimus Monotherapy, American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons, vol.10, issue.12, pp.2604-2618, 2010.

E. J. Brown, M. W. Albers, T. B. Shin, K. Ichikawa, C. T. Keith et al., « A Mammalian Protein Targeted by G1-Arresting Rapamycin-Receptor Complex », Nature, vol.369, issue.6483, pp.756-58, 1994.

R. E. Brown, J. Buryanek, S. Varaha, M. F. Tammisetti, K. Mcguire et al., « Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: Pathogenesis and therapeutic options, Oncotarget, vol.7, issue.27, pp.41612-41633, 2016.

C. J. Bruns, G. E. Koehl, M. Guba, M. Yezhelyev, M. Steinbauer et al., « Rapamycin-Induced Endothelial Cell Death and Tumor Vessel Thrombosis Potentiate Cytotoxic Therapy against Pancreatic Cancer, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol.10, issue.6, pp.2109-2128, 2004.

M. Burnet, « Cancer; a Biological Approach. I. The Processes of Control, British Medical Journal, vol.1, issue.5022, pp.779-86, 1957.

J. M. Campistol, J. Eris, R. Oberbauer, P. Friend, B. Hutchison et al., Sirolimus Therapy after Early Cyclosporine Withdrawal Reduces the Risk for Cancer in Adult Renal Transplantation, Journal of the American Society of Nephrology: JASN, vol.17, issue.2, pp.581-89, 2006.

J. M. Campistol, A. Gutierrez-dalmau, and J. Vicente-torregrosa, Conversion to Sirolimus: A Successful Treatment for Posttransplantation Kaposi's Sarcoma, vol.77, pp.760-62, 2004.

A. B. Campo, J. Del, N. Carretero, F. Aptsiauri, and . Garrido, « Targeting HLA Class I Expression to Increase Tumor Immunogenicity, Tissue Antigens, vol.79, issue.3, pp.147-54, 2012.

L. C. Cantley and B. G. Neel, « New Insights into Tumor Suppression: PTEN Suppresses Tumor Formation by Restraining the Phosphoinositide 3-Kinase/AKT Pathway, Proceedings of the National Academy of Sciences of the United States of America, vol.96, issue.8, pp.4240-4285, 1999.

N. Carayol, E. Vakana, A. Sassano, S. Kaur, D. J. Goussetis et al., « Critical Roles for MTORC2- and Rapamycin-Insensitive MTORC1-Complexes in Growth and Survival of BCR-ABLExpressing Leukemic Cells, Proceedings of the National Academy of Sciences of the United States of America, vol.107, pp.12469-74, 2010.

P. Carmeliet, R. K. Et, and . Jain, « Angiogenesis in Cancer and Other Diseases », Nature, vol.407, issue.6801, pp.249-57, 2000.

E. A. Carswell, L. J. Old, R. L. Kassel, S. Green, N. Fiore et al., « An Endotoxin-Induced Serum Factor That Causes Necrosis of Tumors, Proceedings of the National Academy of Sciences of the United States of America, vol.72, issue.9, pp.3666-70, 1975.

L. Cederbom, H. Hall, and F. Ivars, CD4+CD25+ Regulatory T Cells Down-Regulate CoStimulatory Molecules on Antigen-Presenting Cells, vol.30, pp.1538-1581, 2000.

M. A. Cheever, P. James, A. S. Allison, O. J. Ferris, B. M. Finn et al., « The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of, Translational Research ». Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol.15, issue.17, pp.5323-5360, 2009.

C. Chen, Y. Liu, Y. Liu, . Et-pan, and . Zheng, « MTOR Regulation and Therapeutic Rejuvenation of Aging Hematopoietic Stem Cells, Science Signaling, vol.2, issue.98, p.75, 2009.

D. S. Chen and . Et-ira-mellman, Oncology Meets Immunology: The Cancer-Immunity Cycle, vol.39, 2013.

H. Chi, « Regulation and Function of MTOR Signalling in T Cell Fate Decisions », Nature Reviews. Immunology, vol.12, issue.5, pp.325-363, 2012.

F. Chiarini, C. Evangelisti, J. A. Mccubrey, and A. M. Martelli, « Current Treatment Strategies for Inhibiting MTOR in Cancer, Trends in Pharmacological Sciences, vol.36, issue.2, pp.124-159, 2015.

C. M. Chresta, R. Barry, I. Davies, T. Hickson, S. Harding et al., « AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with in Vitro and in Vivo Antitumor Activity, Cancer Research, vol.70, issue.1, pp.288-98, 2010.

T. F. Cloughesy, P. Koji-yoshimoto, K. Nghiemphu, J. Brown, S. Dang et al., « Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma », PLoS Medicine, vol.5, issue.1, p.8, 2008.

J. J. Coenen, J. P. Hans, E. Koenen, L. B. Van-rijssen, and . Hilbrands, et Irma Joosten. 2006. « Rapamycin, and Not Cyclosporin A, Preserves the Highly Suppressive CD27+ Subset of Human CD4+CD25+ Regulatory T Cells, vol.107, pp.1018-1041

W. B. Coley, « The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases », Am. J. Med. Sci, 1893.

L. W. Collison, J. Creg, T. T. Workman, K. Kuo, Y. Boyd et al., The Inhibitory Cytokine IL-35 Contributes to Regulatory T-Cell Function, vol.450, pp.566-69, 2007.

S. Colombetti, V. Basso, D. L. Mueller, and A. Mondino, « Prolonged TCR/CD28 Engagement Drives IL-2-Independent T Cell Clonal Expansion through Signaling Mediated by the Mammalian Target of Rapamycin », Journal of Immunology, vol.176, issue.5, pp.2730-2768, 1950.

C. A. Corzo, J. Matthew, P. Cotter, F. Cheng, S. Cheng et al., « Mechanism Regulating Reactive Oxygen Species in Tumor-Induced Myeloid-Derived Suppressor Cells », Journal of Immunology, vol.182, issue.9, pp.5693-5701, 1950.

E. Crespo, L. Fernandez, M. Lúcia, E. Melilli, R. Lauzurica et al., « Effector Antitumor and Regulatory T Cell Responses Influence the Development of Nonmelanoma Skin Cancer in Kidney Transplant Patients, Transplantation, vol.101, issue.9, pp.2102-2112, 2017.

J. T. Cunningham, T. Joseph, D. H. Rodgers, F. Arlow, . Vazquez et al., MTOR Controls Mitochondrial Oxidative Function through a YY1-PGC-1alpha Transcriptional Complex, vol.450, pp.736-776, 2007.

T. J. Curiel, G. Coukos, L. Zou, X. Alvarez, P. Cheng et al., « Specific Recruitment of Regulatory T Cells in Ovarian Carcinoma Fosters Immune Privilege and Predicts Reduced Survival », Nature Medicine, vol.10, issue.9, pp.942-991, 2004.

J. M. Curtsinger, M. Christopher, M. F. Johnson, and . Mescher, « CD8 T Cell Clonal Expansion and Development of Effector Function Require Prolonged Exposure to Antigen, Costimulation, and Signal 3 Cytokine », Journal of Immunology, vol.171, issue.10, pp.5165-71, 1950.

J. Dancey, « MTOR Signaling and Drug Development in Cancer, Nature Reviews. Clinical Oncology, vol.7, issue.4, pp.209-228, 2010.

. Deaglio, K. M. Silvia, W. Dwyer, D. Gao, A. Friedman et al., « Adenosine Generation Catalyzed by CD39 and CD73 Expressed on Regulatory T Cells Mediates Immune Suppression, The Journal of Experimental Medicine, vol.204, issue.6, pp.1257-65, 2007.

G. M. Delgoffe, P. Thomas, Y. Kole, P. E. Zheng, K. L. Zarek et al., The MTOR Kinase Differentially Regulates Effector and Regulatory T Cell Lineage Commitment, vol.30, pp.832-876, 2009.

G. M. Delgoffe, N. Kristen, A. T. Pollizzi, E. Waickman, D. J. Heikamp et al., The Kinase MTOR Regulates the Differentiation of Helper T Cells through the Selective Activation of Signaling by MTORC1 and MTORC2 », Nature Immunology, vol.12, issue.4, pp.295-303, 2011.

B. Detti, G. Francolini, C. Becherini, E. Olmetto, I. Giacomelli et al., « Complete Response in Metastatic Renal Cell Carcinoma after Radiotherapy and Everolimus: A Clinical Case and Review of the Literature », Journal of Chemotherapy, vol.28, issue.5, pp.432-466, 2016.

D. Caro, G. , G. F. Castino, F. Bergomas, N. Cortese et al., Tertiary Lymphoid Tissue in the Tumor Microenvironment: From Its Occurrence to Immunotherapeutic Implications, vol.34, pp.123-156, 2015.

. Dieu-nosjean, M. Marie-caroline, C. Antoine, D. Danel, M. Heudes et al., « Long-Term Survival for Patients with Non-Small-Cell Lung Cancer with Intratumoral Lymphoid Structures, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.26, issue.27, pp.4410-4427, 2008.

. Ding, D. H. Zhi-chun, . Munn, G. Et, and . Zhou, « Chemotherapy-Induced Myeloid Suppressor Cells and Antitumor Immunity: The Janus Face of Chemotherapy in Immunomodulation, Oncoimmunology, vol.3, issue.8, p.954471, 2014.

A. C. Donahue, D. A. Et, and . Fruman, « Distinct Signaling Mechanisms Activate the Target of Rapamycin in Response to Different B-Cell Stimuli, European Journal of Immunology, vol.37, issue.10, pp.2923-2959, 2007.

M. Dosset, Y. Godet, C. Vauchy, L. Beziaud, Y. Chun-lone et al., « Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol.18, issue.22, pp.6284-95, 2012.

M. Dosset, C. Vauchy, L. Beziaud, O. Adotevi, Y. Et et al., « Universal Tumor-Reactive Helper Peptides from Telomerase as New Tools for Anticancer Vaccination, Oncoimmunology, vol.2, issue.3, p.23430, 2013.

J. Douros, M. Et, and . Suffness, New Antitumor Substances of Natural Origin, vol.8, pp.63-87, 1981.

R. J. Dowling, I. Topisirovic, T. Alain, M. Bidinosti, B. D. Fonseca et al., MTORC1-Mediated Cell Proliferation, but Not Cell Growth, Controlled by the 4E-BPs ». Science, vol.328, pp.1172-76, 2010.

D. Ducloux, J. Bamoulid, C. Courivaud, B. Gaugler, J. Rebibou et al., et Philippe Saas. 2011. « Thymic Function, Anti-Thymocytes Globulins, and Cancer after Renal Transplantation, vol.25, pp.56-60

K. Dunker, G. Schlaf, J. Bukur, W. W. Altermann, D. Handke et al., « Expression and Regulation of Non-Classical HLA-G in Renal Cell Carcinoma, Tissue Antigens, vol.72, issue.2, pp.137-185, 2008.

G. P. Dunn, J. Lloyd, R. D. Old, and . Schreiber, « The Three Es of Cancer Immunoediting, Annual Review of Immunology, vol.22, pp.329-60, 2004.

. Düvel, J. L. Katrin, S. Yecies, P. Menon, A. I. Raman et al., « Activation of a Metabolic Gene Regulatory Network Downstream of MTOR Complex 1 », Molecular Cell, vol.39, issue.2, pp.171-83, 2010.

A. Efeyan, M. David, and . Sabatini, « MTOR and Cancer: Many Loops in One Pathway ». Current Opinion in, Cell Biology, vol.22, issue.2, pp.169-76, 2010.

A. M. Eiden, S. Zhang, J. M. Gary, J. K. Simmons, and B. A. Mock, « Molecular Pathways: Increased Susceptibility to Infection Is a Complication of MTOR Inhibitor Use in Cancer Therapy, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol.22, issue.2, pp.277-83, 2016.

E. Elkord, S. Sharma, D. J. Burt, and R. E. Hawkins, « Expanded Subpopulation of FoxP3+ T Regulatory Cells in Renal Cell Carcinoma Co-Express Helios, Clinical Immunology, vol.140, issue.3, pp.218-240, 2011.

S. Euvrard, E. Morelon, L. Rostaing, E. Goffin, A. Brocard et al., Sirolimus and Secondary Skin-Cancer Prevention in Kidney Transplantation, The New England Journal of Medicine, vol.367, issue.4, pp.329-368, 2012.

S. Faes, N. Demartines, O. Et, and . Dormond, Resistance to MTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity ». Oxidative Medicine and Cellular Longevity, p.1726078, 2017.

S. Faivre, G. Kroemer, E. Et, and . Raymond, « Current Development of MTOR Inhibitors as Anticancer Agents », Nature Reviews. Drug Discovery, vol.5, issue.8, pp.671-88, 2006.

Q. Fan, O. Aksoy, R. A. Wong, S. Ilkhanizadeh, C. J. Novotny et al., « A Kinase Inhibitor Targeted to MTORC1 Drives Regression in Glioblastoma, Cancer Cell, vol.31, issue.3, pp.424-459, 2017.

Y. Fan, Z. Liu, X. Fang, Z. Ge, N. Ge et al., « Differential Expression of Full-Length Telomerase Reverse Transcriptase MRNA and Telomerase Activity between Normal and Malignant Renal Tissues, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol.11, issue.12, pp.4331-4368, 2005.

Z. Feng, H. Zhang, A. J. Levine, and . Et-shengkan-jin, « The Coordinate Regulation of the P53 and MTOR Pathways in Cells, Proceedings of the National Academy of Sciences of the United States of America, vol.102, pp.8204-8213, 2005.

D. Finlay and D. A. Cantrell, Metabolism, Migration and Memory in Cytotoxic T Cells, vol.11, pp.109-126, 2011.

C. Fiorini, F. Massari, S. Pedron, S. Sanavio, C. Ciccarese et al., « Methods to Identify Molecular Expression of MTOR Pathway: A Rationale Approach to Stratify Patients Affected by Clear Cell Renal Cell Carcinoma for More Likely Response to MTOR Inhibitors, American Journal of Cancer Research, vol.4, issue.6, pp.907-922, 2014.

M. Fouladi, F. Laningham, J. Wu, M. A. O'shaughnessy, K. Molina et al., « Phase I Study of Everolimus in Pediatric Patients with Refractory Solid Tumors, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.25, issue.30, pp.4806-4818, 2007.

K. M. Fracchia, Y. Christine, C. M. Pai, and . Walsh, « Modulation of T Cell Metabolism and Function through Calcium Signaling, Frontiers in Immunology, vol.4, p.324, 2013.

L. M. Francisco, H. Victor, K. E. Salinas, V. K. Brown, G. J. Vanguri et al., « PD-L1 regulates the development, maintenance, and function of induced regulatory T cells, The Journal of Experimental Medicine, vol.206, issue.13, pp.3015-3044, 2009.

W. H. Fridman, L. Zitvogel, C. Sautès-fridman, and G. Kroemer, « The Immune Contexture in Cancer Prognosis and Treatment », Nature Reviews. Clinical Oncology, juillet, 2017.

W. Fridman, F. Herman, C. Pagès, and . Sautès-fridman, et Jérôme Galon. 2012. « The Immune Contexture in Human Tumours: Impact on Clinical Outcome, vol.12, pp.298-306

W. Fridman and . Hervé, « Historique de l'immunothérapie. Changement de paradigme ?, Bulletin du cancer, vol.103, issue.16, p.30368, 2016.

J. Galon, A. Costes, F. Sanchez-cabo, A. Kirilovsky, B. Mlecnik et al., « Type, Density, and Location of Immune Cells within Human Colorectal Tumors Predict Clinical Outcome, Science, vol.313, issue.5795, pp.1960-64, 2006.

I. G. Ganley, H. Du, J. Lam, X. Wang, S. Ding et al., et Xuejun Jiang. 2009. « ULK1.ATG13.FIP200 Complex Mediates MTOR Signaling and Is Essential for Autophagy, vol.284, pp.12297-305

C. A. Garcia, S. Et, and . Wu, « Attributable Risk of Infection to MTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer, Cancer Investigation, vol.34, issue.10, pp.521-551, 2016.

J. M. García-martínez, D. R. Et, and . Alessi, « MTOR Complex 2 (MTORC2) Controls Hydrophobic Motif Phosphorylation and Activation of Serum- and GlucocorticoidInduced Protein Kinase 1 (SGK1), The Biochemical Journal, vol.416, issue.3, pp.375-85, 2008.

L. Gattinoni, E. Lugli, Y. Ji, Z. Pos, C. M. Paulos et al., A Human Memory T Cell Subset with Stem Cell-like Properties », Nature Medicine, vol.17, issue.10, pp.1290-97, 2011.

A. Gaumann, H. J. Schlitt, and E. K. Geissler, « Immunosuppression and Tumor Development in Organ Transplant Recipients: The Emerging Dualistic Role of Rapamycin, Transplant International: Official Journal of the European Society for Organ Transplantation, vol.21, issue.3, pp.207-224, 2008.

D. Generali, G. Bates, A. Berruti, M. P. Brizzi, L. Campo et al., « Immunomodulation of FOXP3+ Regulatory T Cells by the Aromatase Inhibitor Letrozole in Breast Cancer Patients, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol.15, issue.3, pp.1046-51, 2009.

V. A. Gerriets, J. C. Et, and . Rathmell, Metabolic Pathways in T Cell Fate and Function, vol.33, pp.168-73, 2012.

D. A. Gewirtz, « Autophagy and Senescence in Cancer Therapy, Journal of Cellular Physiology, vol.229, issue.1, pp.6-9, 2014.

F. Ghiringhelli, C. Menard, P. E. Puig, S. Ladoire, S. Roux et al.,

C. «-metronomic, Regimen Selectively Depletes CD4+CD25+ Regulatory T Cells and Restores T and NK Effector Functions in End Stage Cancer Patients, Cancer Immunology, Immunotherapy: CII, vol.56, issue.5, pp.641-689

. Ghiringhelli, P. E. François, S. Puig, A. Roux, E. Parcellier et al., Tumor Cells Convert Immature Myeloid Dendritic Cells into TGF-Beta-Secreting Cells Inducing CD4+CD25+ Regulatory T Cell Proliferation, vol.202, pp.919-948, 2005.

N. A. Giraldo, E. Becht, F. Pagès, G. Skliris, V. Verkarre et al., « Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol.21, issue.13, pp.3031-3071, 2015.

N. A. Giraldo, E. Becht, Y. Vano, F. Petitprez, L. Lacroix et al., « Tumor-Infiltrating and Peripheral Blood T-Cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol.23, issue.15, pp.4416-4444, 2017.

M. Gobert, I. Treilleux, N. Bendriss-vermare, T. Bachelot, S. Goddard-leon et al., « Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome, Cancer Research, vol.69, issue.5, pp.2000-2009, 2009.

Y. Godet, E. Fabre, M. Dosset, M. Lamuraglia, E. Levionnois et al., Analysis of Spontaneous TumorSpecific CD4 T-Cell Immunity in Lung Cancer Using Promiscuous HLA-DR TelomeraseDerived Epitopes: Potential Synergistic Effect with Chemotherapy Response, vol.18, pp.2943-53, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00723050

E. A. Goncharova, A. Dmitry, G. Goncharov, O. Damera, Y. Tliba et al., « Signal Transducer and Activator of Transcription 3 Is Required for Abnormal Proliferation and Survival of TSC2-Deficient Cells: Relevance to Pulmonary Lymphangioleiomyomatosis, Molecular Pharmacology, vol.76, issue.4, pp.766-77, 2009.

J. M. Grayson, A. J. Zajac, J. D. Altman, and E. R. Ahmed, « Cutting Edge: Increased Expression of Bcl-2 in Antigen-Specific Memory CD8+ T Cells », Journal of Immunology, vol.164, issue.8, pp.3950-54, 1950.

W. J. Grossman, W. James, B. L. Verbsky, C. Tollefsen, J. P. Kemper et al., « Differential Expression of Granzymes A and B in Human Cytotoxic Lymphocyte Subsets and T Regulatory Cells, Blood, vol.104, issue.9, pp.2840-2888, 2004.

C. G. Groth, L. Bäckman, J. M. Morales, R. Calne, H. Kreis et al., Sirolimus (Rapamycin)-Based Therapy in Human Renal Transplantation: Similar Efficacy and Different Toxicity Compared with Cyclosporine. Sirolimus European Renal Transplant Study Group, Transplantation, vol.67, issue.7, pp.1036-1078, 1999.

A. E. Grulich, T. Marina, M. O. Van-leeuwen, C. M. Falster, and . Vajdic, « Incidence of Cancers in People with HIV/AIDS Compared with Immunosuppressed Transplant Recipients: A Meta-Analysis, Lancet, vol.370, issue.9581, pp.61050-61052, 2007.

M. Guba, M. Philipp-von-breitenbuch, G. Steinbauer, S. Koehl, M. Flegel et al., « Rapamycin Inhibits Primary and Metastatic Tumor Growth by Antiangiogenesis: Involvement of Vascular Endothelial Growth Factor », Nature Medicine, vol.8, issue.2, pp.128-163, 2002.

D. A. Guertin, D. M. Et, and . Sabatini, « Defining the Role of mTOR in Cancer », Cancer Cell, vol.12, issue.1, pp.9-22, 2007.

S. Hahn, T. Stalder, M. Wernli, D. Bürgin, J. Tschopp et al., « DownModulation of CD4+ T Helper Type 2 and Type 0 Cells by T Helper Type 1 Cells via Fas/Fas-Ligand Interaction, European Journal of Immunology, vol.25, issue.9, pp.2679-85, 1995.

J. D. Hainsworth, R. David, H. A. Spigel, D. Burris, B. L. Waterhouse et al., « Phase II Trial of Bevacizumab and Everolimus in Patients with Advanced Renal Cell Carcinoma », Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.28, issue.13, pp.2131-2167, 2010.

P. F. Halloran, « Immunosuppressive Drugs for Kidney Transplantation, The New England Journal of Medicine, vol.351, issue.26, pp.2715-2744, 2004.

D. Hanahan, R. A. Et, and . Weinberg, « The Hallmarks of Cancer, Cell, vol.100, issue.1, pp.57-70, 2000.

D. Hanahan and R. A. Weinberg, « Hallmarks of Cancer: The next Generation, Cell, vol.144, issue.5, pp.646-74, 2011.

K. Hara, K. Yonezawa, Q. P. Weng, M. T. Kozlowski, C. Belham et al., « Amino Acid Sufficiency and MTOR Regulate P70 S6 Kinase and EIF-4E BP1 through a Common Effector Mechanism, The Journal of Biological Chemistry, vol.273, issue.23, pp.14484-94, 1998.

L. E. Harrington, D. Robin, P. R. Hatton, H. Mangan, T. L. Turner et al., , 2005.

T. Effector and . Cells, Develop via a Lineage Distinct from the T Helper Type, vol.1

». Lineages, Nature Immunology, vol.6, issue.11, pp.1123-1155

D. Hartley and G. M. Cooper, « Role of MTOR in the Degradation of IRS-1: Regulation of PP2A Activity », Journal of Cellular Biochemistry, vol.85, issue.2, pp.304-318, 2002.

S. Haxhinasto, D. Mathis, C. Et, and . Benoist, « The AKT-MTOR Axis Regulates de Novo Differentiation of CD4+Foxp3+ Cells, The Journal of Experimental Medicine, vol.205, issue.3, pp.565-74, 2008.

J. Heitman, N. R. Movva, and M. N. Hall, « Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast, Science, vol.253, issue.5022, pp.905-914, 1991.

T. K. Hendrikx, H. L. Jurjen, M. Velthuis, E. Klepper, A. Van-gurp et al., « Monotherapy Rapamycin Allows an Increase of CD4 CD25 FoxP3 T Cells in Renal Recipients, Transplant International: Official Journal of the European Society for Organ Transplantation, vol.22, issue.9, pp.884-91, 2009.

G. Hess, R. Herbrecht, J. Romaguera, G. Verhoef, M. Crump et al., « Phase III Study to Evaluate Temsirolimus Compared with Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.27, issue.23, pp.3822-3851, 2009.

E. Hiyama and K. Hiyama, Telomerase as Tumor Marker, vol.194, pp.221-254, 2003.

M. Hojo, T. Morimoto, M. Maluccio, T. Asano, K. Morimoto et al., « Cyclosporine Induces Cancer Progression by a CellAutonomous Mechanism », Nature, vol.397, issue.6719, pp.530-564, 1999.

M. K. Holz, « The Role of S6K1 in ER-Positive Breast Cancer, Cell Cycle, vol.11, issue.17, pp.3159-65, 2012.

H. Hosoi, M. B. Dilling, T. Shikata, L. N. Liu, L. Shu et al., « Rapamycin Causes Poorly Reversible Inhibition of MTOR and Induces P53-Independent Apoptosis in Human Rhabdomyosarcoma Cells, Cancer Research, vol.59, issue.4, pp.886-94, 1999.

N. Hosokawa, T. Hara, T. Kaizuka, C. Kishi, A. Takamura et al., Nutrient-Dependent MTORC1 Association with the ULK1-Atg13-FIP200 Complex Required for Autophagy, vol.20, pp.1981-91, 2009.

A. C. Hsieh, M. Costa, O. Zollo, C. Davis, M. E. Feldman et al., « Genetic Dissection of the Oncogenic MTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-EIF4E », Cancer Cell, vol.17, issue.3, pp.249-61, 2010.

S. Huang, S. Apasov, M. Koshiba, and M. Sitkovsky, « Role of A2a Extracellular Adenosine Receptor-Mediated Signaling in Adenosine-Mediated Inhibition of T-Cell Activation and Expansion, Blood, vol.90, issue.4, pp.1600-1610, 1997.

G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin et al., « Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma, The New England Journal of Medicine, vol.356, issue.22, pp.2271-81, 2007.

G. R. Hudes, « Targeting MTOR in Renal Cell Carcinoma ». Cancer, vol.115, pp.2313-2333, 2009.

K. Hung, R. Hayashi, A. Lafond-walker, C. Lowenstein, D. Pardoll et al., The Central Role of CD4(+) T Cells in the Antitumor Immune Response, vol.188, pp.2357-68, 1998.

A. Iellem, M. Mariani, R. Lang, H. Recalde, P. Panina-bordignon et al., « Unique Chemotactic Response Profile and Specific Expression of Chemokine Receptors CCR4 and CCR8 by CD4(+)CD25(+) Regulatory T Cells, The Journal of Experimental Medicine, vol.194, issue.6, pp.847-53, 2001.

K. Inoki, Y. Li, T. Zhu, J. Wu, and . Et-kun-liang-guan, « TSC2 Is Phosphorylated and Inhibited by Akt and Suppresses MTOR Signalling », Nature Cell Biology, vol.4, issue.9, pp.648-57, 2002.

K. Iwasaki, W. Obara, T. Et, and . Fujioka, « Case of Complete Response to Everolimus for Metastatic Renal Cell Carcinoma, International Journal of Urology: Official Journal of the Japanese Urological Association, vol.19, issue.9, pp.891-92, 2012.

E. Jacinto, V. Facchinetti, D. Liu, N. Soto, S. Wei et al., « SIN1/MIP1 Maintains Rictor-MTOR Complex Integrity and Regulates Akt Phosphorylation and Substrate Specificity, Cell, vol.127, issue.1, pp.125-162, 2006.

E. Jacinto, R. Loewith, A. Schmidt, S. Lin, M. A. Rüegg et al., « Mammalian TOR Complex 2 Controls the Actin Cytoskeleton and Is Rapamycin Insensitive », Nature Cell Biology, vol.6, issue.11, pp.1122-1150, 2004.

. Jagannath, D. R. Chinnaswamy, S. Lindsey, Y. Dhandayuthapani, R. L. Xu et al., « Autophagy Enhances the Efficacy of BCG Vaccine by Increasing Peptide Presentation in Mouse Dendritic Cells », Nature Medicine, vol.15, issue.3, pp.267-76, 2009.

C. Jung, C. Hwa, S. Bong-jun, Y. Ro, N. M. Kim et al., ULK-Atg13-FIP200 Complexes Mediate MTOR Signaling to the Autophagy Machinery, vol.20, pp.1992-2003, 2009.

S. M. Kaech, T. Joyce, E. J. Tan, . Wherry, T. Bogumila et al., Selective Expression of the Interleukin 7 Receptor Identifies Effector CD8 T Cells That Give Rise to Long-Lived Memory Cells, vol.4, pp.1191-98, 2003.

B. D. Kahan, K. L. Napoli, P. A. Kelly, J. Podbielski, I. Hussein et al., Therapeutic Drug Monitoring of Sirolimus: Correlations with Efficacy and Toxicity, vol.14, pp.97-109, 2000.

T. Kaizuka, T. Hara, N. Oshiro, U. Kikkawa, K. Yonezawa et al., Shun-Ichiro Iemura, Tohru Natsume, et Noboru Mizushima. 2010. « Tti1 and Tel2 Are Critical Factors in Mammalian Target of Rapamycin Complex Assembly, vol.285, pp.20109-20125

R. Kanesvaran, K. Watt, J. D. Turnbull, A. J. Armstrong, M. Cohen-wolkowiez et al., « A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma, Clinical Genitourinary Cancer, vol.13, issue.4, pp.319-346, 2015.

. Kantidakis, B. A. Theodoros, J. L. Ramsbottom, S. N. Birch, . Dowding et al., « MTOR Associates with TFIIIC, Is Found at TRNA and 5S RRNA Genes, and Targets Their Repressor Maf1, Proceedings of the National Academy of Sciences of the United States of America, vol.107, pp.11823-11851, 2010.

S. D. Katzman, E. William, A. V. O'gorman, E. Villarino, R. S. Gallo et al., « Duration of Antigen Receptor Signaling Determines T-Cell Tolerance or Activation, Proceedings of the National Academy of Sciences of the United States of America, vol.107, 2010.

H. Kauffman, W. S. Myron, Y. Cherikh, D. W. Cheng, B. D. Hanto et al., « Maintenance Immunosuppression with Target-of-Rapamycin Inhibitors Is Associated with a Reduced Incidence of de Novo Malignancies, Transplantation, vol.80, issue.7, pp.883-89, 2005.

B. Kellersch and T. Brocker, « Langerhans Cell Homeostasis in Mice Is Dependent on MTORC1 but Not MTORC2 Function, Blood, vol.121, issue.2, pp.298-307, 2013.

R. Kennedy and E. Celis, « Multiple Roles for CD4+ T Cells in Anti-Tumor Immune Responses, Immunological Reviews, vol.222, pp.129-173, 2008.

Y. M. Kerdiles, R. Daniel, R. Beisner, A. S. Tinoco, D. H. Dejean et al., Foxo1 Links Homing and Survival of Naive T Cells by Regulating L-Selectin, CCR7 and Interleukin 7 Receptor, vol.10, pp.176-84, 2009.

. Kim, I. Byung-seok, Y. Kim, Y. Park, Y. Kim et al., Conversion of Th2 Memory Cells into Foxp3+ Regulatory T Cells Suppressing Th2-Mediated Allergic Asthma, vol.107, pp.8742-8789, 2010.

D. H. Kim and D. M. Sabatini, « Raptor and MTOR: Subunits of a Nutrient-Sensitive Complex, Current Topics in Microbiology and Immunology, vol.279, pp.259-70, 2004.

. Kim, D. D. Do-hyung, . Sarbassov, M. Siraj, J. E. Ali et al., « MTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex That Signals to the Cell Growth Machinery, Cell, vol.110, issue.2, pp.163-75, 2002.

. Kim, D. D. Do-hyung, . Sarbassov, M. Siraj, R. R. Ali et al., « GbetaL, a Positive Regulator of the Rapamycin-Sensitive Pathway Required for the Nutrient-Sensitive Interaction between Raptor and MTOR », Molecular Cell, vol.11, issue.4, pp.895-904, 2003.

H. Klümpen, J. H. Beijnen, and H. Gurney, et Jan H. M. Schellens. 2010. « Inhibitors of MTOR, vol.15, pp.1262-69

S. D. Knight, D. Nicholas, J. L. Adams, A. M. Burgess, M. G. Chaudhari et al., « Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin, ACS Medicinal Chemistry Letters, vol.1, issue.1, pp.39-43, 2010.

M. Kobayashi, T. Kubo, K. Komatsu, A. Fujisaki, F. Terauchi et al., Shinsuke Kurokawa, et Tatsuo Morita. 2013. « Changes in Peripheral Blood Immune Cells: Their Prognostic Significance in Metastatic Renal Cell Carcinoma Patients Treated with Molecular Targeted Therapy, Medical Oncology, vol.30, issue.2, p.556

. Kopf, G. M. Heather, O. M. De-la-rosa, . Zack-howard, and . Et-xin-chen, « Rapamycin Inhibits Differentiation of Th17 Cells and Promotes Generation of FoxP3+ T Regulatory Cells, International Immunopharmacology, vol.7, issue.13, pp.1819-1843, 2007.

I. Koren, E. Reem, A. Et, and . Kimchi, « Autophagy Gets a Brake: DAP1, a Novel MTOR Substrate, Is Activated to Suppress the Autophagic Process, Autophagy, vol.6, issue.8, pp.1179-80, 2010.

A. Kornakiewicz, W. Solarek, Z. F. Bielecka, F. Lian, C. Szczylik et al., « Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma, Current Signal Transduction Therapy, vol.8, issue.3, pp.210-228, 2014.

G. Kroemer, L. Galluzzi, O. Kepp, L. Et, and . Zitvogel, « Immunogenic Cell Death in Cancer Therapy, Annual Review of Immunology, vol.31, pp.51-72, 2013.

J. Kunz, R. Henriquez, U. Schneider, M. Deuter-reinhard, N. R. Movva et al., « Target of Rapamycin in Yeast, TOR2, Is an Essential Phosphatidylinositol Kinase Homolog Required for G1 Progression, Cell, vol.73, issue.3, pp.585-96, 1993.

D. J. Kwiatkowski, Rhebbing up MTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis, vol.2, pp.471-76, 2003.

L. Laar, M. Van-de, F. M. Buitenhuis, . Wensveen, L. A. Harry et al., « Human CD34-Derived Myeloid Dendritic Cell Development Requires Intact Phosphatidylinositol 3-Kinase-Protein Kinase BMammalian Target of Rapamycin Signaling », Journal of Immunology, vol.184, issue.12, pp.6600-6611, 1950.

S. Ladoire, L. Arnould, G. Mignot, L. Apetoh, C. Rébé et al., « T-Bet Expression in Intratumoral Lymphoid Structures after Neoadjuvant Trastuzumab plus Docetaxel for HER2-Overexpressing Breast Carcinoma Predicts Survival, British Journal of Cancer, vol.105, issue.3, pp.366-71, 2011.

C. Laheurte, J. Galaine, L. Beziaud, M. Dosset, J. Kerzerho et al., « Immunoprevalence and Magnitude of HLA-DP4 versus HLA-DR-Restricted Spontaneous CD4(+) Th1 Responses against Telomerase in Cancer Patients, Oncoimmunology, vol.5, issue.5, p.1137416, 2016.

K. Lahl, C. Loddenkemper, C. Drouin, J. Freyer, J. Arnason et al.,

, « Selective Depletion of Foxp3+ Regulatory T Cells Induces a Scurfy-like Disease, vol.204, pp.57-63

M. Laplante and D. M. Sabatini, « Regulation of MTORC1 and Its Impact on Gene Expression at a Glance », Journal of Cell Science, vol.126, pp.1713-1732, 2013.

H. Lee, L. M. Kyu, B. E. Mattei, P. Steinberg, Y. H. Alberts et al., et Akiko Iwasaki. 2010. « In Vivo Requirement for Atg5 in Antigen Presentation by Dendritic Cells, vol.32, pp.227-266

M. O. Li, S. Sanjabi, R. A. Et, and . Flavell, « Transforming Growth FactorBeta Controls Development, Homeostasis, and Tolerance of T Cells by Regulatory T Cell-Dependent and -Independent Mechanisms, Immunity, vol.25, issue.3, pp.455-71, 2006.

. Li, R. R. Qingsheng, K. Rao, K. Araki, K. Pollizzi et al., A Central Role for MTOR Kinase in Homeostatic Proliferation Induced CD8+ T Cell Memory and Tumor Immunity, Immunity, vol.34, issue.4, pp.541-53, 2011.

B. Liang, C. Workman, J. Lee, C. Chew, B. M. Dale et al., « Regulatory T Cells Inhibit Dendritic Cells by Lymphocyte Activation Gene-3 Engagement of MHC Class II », Journal of Immunology, vol.180, issue.9, pp.5916-5942, 1950.

G. Liu, S. Burns, G. Huang, K. Boyd, R. L. Proia et al., « The Receptor S1P1 Overrides Regulatory T Cell-Mediated Immune Suppression through Akt-MTOR », Nature Immunology, vol.10, issue.7, pp.769-77, 2009.

G. Liu, K. Yang, S. Burns, S. Shrestha, H. Et et al., « The S1P(1)-MTOR Axis Directs the Reciprocal Differentiation of T(H)1 and T(Reg) Cells », Nature Immunology, vol.11, issue.11, pp.1047-56, 2010.

X. Ma, J. Max, and . Blenis, « Molecular Mechanisms of MTOR-Mediated Translational Control », Nature Reviews. Molecular Cell Biology, vol.10, issue.5, pp.307-325, 2009.

A. S. Macdonald and . Study-group, « A Worldwide, Phase III, Randomized, Controlled, Safety and Efficacy Study of a Sirolimus/Cyclosporine Regimen for Prevention of Acute Rejection in Recipients of Primary Mismatched Renal Allografts, Transplantation, vol.71, issue.2, pp.271-80, 2001.

N. J. Maciver, J. Blagih, D. C. Saucillo, L. Tonelli, T. Griss et al., « The Liver Kinase B1 Is a Central Regulator of T Cell Development, Activation, and Metabolism », Journal of Immunology, vol.187, issue.8, pp.4187-98, 1950.

S. Maira, F. Stauffer, J. Brueggen, P. Furet, C. Schnell et al., « Identification and Characterization of NVP-BEZ235, a New Orally Available Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor with Potent in Vivo Antitumor Activity, Molecular Cancer Therapeutics, vol.7, issue.7, pp.1851-63, 2008.

Y. Mamane, E. Petroulakis, O. Lebacquer, and N. Sonenberg, « MTOR, Translation Initiation and Cancer, Oncogene, vol.25, issue.48, pp.6416-6438, 2006.

J. B. Mannick, G. Del-giudice, M. Lattanzi, N. M. Valiante, J. Praestgaard et al., « MTOR Inhibition Improves Immune Function in the Elderly », Science Translational Medicine, vol.6, issue.268, pp.268-179, 2014.

A. Marçais and T. Walzer, « MTOR: A Gate to NK Cell Maturation and Activation, Cell Cycle, vol.13, issue.21, pp.3315-3331, 2014.

P. Martínez, A. María, and . Blasco, Telomeric and Extra-Telomeric Roles for Telomerase and the Telomere-Binding Proteins, vol.11, pp.161-76, 2011.

S. L. Maude, N. Frey, P. A. Shaw, R. Aplenc, D. M. Barrett et al., Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia, vol.371, pp.1507-1524, 2014.

C. Mayer, J. Zhao, X. Yuan, I. Et, and . Grummt, « MTOR-Dependent Activation of the Transcription Factor TIF-IA Links RRNA Synthesis to Nutrient Availability, Genes & Development, vol.18, issue.4, pp.423-457, 2004.

A. L. Mellor, D. H. Et, and . Munn, « IDO Expression by Dendritic Cells: Tolerance and Tryptophan Catabolism », Nature Reviews. Immunology, vol.4, issue.10, pp.762-74, 2004.

J. A. Menendez, R. Et, and . Lupu, « Fatty Acid Synthase and the Lipogenic Phenotype in Cancer Pathogenesis », Nature Reviews. Cancer, vol.7, issue.10, pp.763-77, 2007.

C. Ménétrier-caux, T. Curiel, J. Faget, M. Manuel, C. Caux et al., Targeting Regulatory T Cells, vol.7, pp.15-28, 2012.

R. D. Michalek, C. Jeffrey, and . Rathmell, « The Metabolic Life and Times of a T-Cell », Immunological Reviews, vol.236, pp.190-202, 2010.

N. Mirza, M. Fishman, I. Fricke, M. Dunn, A. M. Neuger et al., et Dmitry I. Gabrilovich. 2006. « All-TransRetinoic Acid Improves Differentiation of Myeloid Cells and Immune Response in Cancer Patients, Cancer Research, vol.66, issue.18, pp.9299-9307

Y. Mizukami, K. Kono, Y. Kawaguchi, H. Akaike, K. Kamimura et al., « CCL17 and CCL22 Chemokines within Tumor Microenvironment Are Related to Accumulation of Foxp3+ Regulatory T Cells in Gastric Cancer, International Journal of Cancer, vol.122, issue.10, pp.2286-93, 2008.

A. M. Molina, R. Darren, M. H. Feldman, M. S. Voss, M. S. Ginsberg et al., « Phase 1 Trial of Everolimus plus Sunitinib in Patients with Metastatic Renal Cell Carcinoma, Cancer, vol.118, issue.7, pp.1868-76, 2012.

T. R. Mosmann, H. Cherwinski, M. W. Bond, M. A. Giedlin, and R. L. Coffman, « Two Types of Murine Helper T Cell Clone. I. Definition According to Profiles of Lymphokine Activities and Secreted Proteins, Journal of Immunology, vol.175, issue.1, pp.5-14, 1950.

G. T. Motz, G. Et, and . Coukos, « Deciphering and Reversing Tumor Immune Suppression, Immunity, vol.39, issue.1, pp.61-73, 2013.

R. J. Motzer, B. Escudier, S. Oudard, T. E. Hutson, C. Porta et al., « Efficacy of Everolimus in Advanced Renal Cell Carcinoma: A Double-Blind, Randomised, Placebo-Controlled Phase III Trial, Lancet, vol.372, issue.9637, pp.61039-61048, 2008.

K. Movahedi, M. Guilliams, J. Van-den, R. Bossche, . Van-den et al., Identification of Discrete Tumor-Induced Myeloid-Derived Suppressor Cell Subpopulations with Distinct T Cell-Suppressive Activity, vol.111, pp.4233-4277, 2008.

T. Nakamura, T. Nakao, N. Yoshimura, and E. E. Ashihara, « Rapamycin Prolongs Cardiac Allograft Survival in a Mouse Model by Inducing Myeloid-Derived Suppressor Cells, American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2015.

. Namba, L. J. Ruria, C. K. Young, L. Abbey, P. Kim et al., « Rapamycin Inhibits Growth of Premalignant and Malignant Mammary Lesions in a Mouse Model of Ductal Carcinoma in Situ, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol.12, issue.8, pp.2613-2634, 2006.

K. Namura, S. Otake, T. Sawada, A. Fujikawa, J. Ota et al., « [PATHOLOGICAL COMPLETE RESPONSE WITH EVEROLIMUS FOR MULTIPLE LUNG METASTASES OF RENAL CELL CARCINOMA RESISTANT TO SUNITINIB] ». Nihon Hinyokika Gakkai Zasshi, The Japanese Journal of Urology, vol.106, issue.1, pp.30-34, 2015.

H. Nishikawa and S. Sakaguchi, « Regulatory T Cells in Tumor Immunity, International Journal of Cancer, vol.127, issue.4, pp.759-67, 2010.

M. Noris, F. Casiraghi, M. Todeschini, P. Cravedi, D. Cugini et al., Regulatory T Cells and T Cell Depletion: Role of Immunosuppressive Drugs, vol.18, pp.1007-1025, 2007.

J. Nourse, E. Firpo, W. M. Flanagan, S. Coats, K. Polyak et al., « Interleukin-2-Mediated Elimination of the P27Kip1 Cyclin-Dependent Kinase Inhibitor Prevented by Rapamycin », Nature, vol.372, issue.6506, pp.570-73, 1994.

T. F. O'brien, K. Balachandra, D. Gorentla, S. Xie, I. X. Srivatsan et al., « Regulation of T-Cell Survival and Mitochondrial Homeostasis by TSC1, European Journal of Immunology, vol.41, issue.11, pp.3361-70, 2011.

A. O'donnell, S. Faivre, H. A. Burris, D. Rea, V. Papadimitrakopoulou et al., « Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients with Advanced Solid Tumors, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.26, issue.10, pp.1588-95, 2008.

J. J. O'shea, E. Et-william, and . Paul, Mechanisms Underlying Lineage Commitment and Plasticity of Helper CD4+ T Cells ». Science, vol.327, pp.1098-1102, 2010.

S. Ostrand-rosenberg, « CD4+ T Lymphocytes: A Critical Component of Antitumor Immunity, Cancer Investigation, vol.23, issue.5, pp.413-432, 2005.

W. Ouyang, O. Beckett, R. A. Flavell, and M. O. Li, « An Essential Role of the Forkhead-Box Transcription Factor Foxo1 in Control of T Cell Homeostasis and Tolerance, Immunity, vol.30, issue.3, pp.358-71, 2009.

F. Pagès, A. Berger, M. Camus, F. Sanchez-cabo, A. Costes et al., Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer, vol.353, pp.2654-66, 2005.

N. Pallet, E. Thervet, and C. Legendre, et Dany Anglicheau. 2006. « Sirolimus Early Graft Nephrotoxicity: Clinical and Experimental Data, vol.1, pp.179-87

M. T. Pallotta, C. Orabona, C. Volpi, C. Vacca, M. L. Belladonna et al., « Indoleamine 2,3-Dioxygenase Is a Signaling Protein in Long-Term Tolerance by Dendritic Cells », Nature Immunology, vol.12, issue.9, pp.870-78, 2011.

P. Pandiyan, L. Zheng, S. Ishihara, J. Reed, and M. J. Lenardo, « CD4+CD25+Foxp3+ Regulatory T Cells Induce Cytokine Deprivation-Mediated Apoptosis of Effector CD4+ T Cells », Nature Immunology, vol.8, issue.12, pp.1353-62, 2007.

C. A. Parachoniak, A. Rankin, B. Gaffney, R. Hartmaier, D. Spritz et al., « Exceptional Durable Response to Everolimus in a Patient with Biphenotypic Breast Cancer Harboring an STK11 Variant ». Cold Spring Harbor Molecular Case Studies, 2017.

D. M. Pardoll and S. L. Topalian, The Role of CD4+ T Cell Responses in Antitumor Immunity, vol.10, pp.588-94, 1998.

D. M. Pardoll, « The Blockade of Immune Checkpoints in Cancer Immunotherapy », Nature Reviews. Cancer, vol.12, issue.4, pp.252-64, 2012.

J. Park, M. Hyun, Y. S. Ryu, S. R. Park, Y. Park et al., « Successful Control of Heavily Pretreated Metastatic Gastric Cancer with the MTOR Inhibitor Everolimus (RAD001) in a Patient with PIK3CA Mutation and PS6 Overexpression, BMC Cancer, vol.15, p.119, 2015.

Y. Park, H. Jin, J. Lopez, C. Elly, G. Kim et al., TSC1 Regulates the Balance between Effector and Regulatory T Cells, vol.123, pp.5165-78, 2013.

M. E. Pavel, D. John, E. Hainsworth, M. Baudin, D. Peeters et al., Everolimus plus Octreotide Long-Acting Repeatable for the Treatment of Advanced Neuroendocrine Tumours Associated with Carcinoid Syndrome (RADIANT-2): A Randomised, 2011.

». Study, Lancet, vol.378, issue.9808, p.61742

H. Pere, C. Tanchot, J. Bayry, M. Terme, J. Taieb et al., « Comprehensive Analysis of Current Approaches to Inhibit Regulatory T Cells in Cancer, Oncoimmunology, vol.1, issue.3, pp.326-359, 2012.

T. R. Peterson, M. Laplante, C. C. Thoreen, Y. Sancak, A. Seong et al., « DEPTOR Is an MTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival, Cell, vol.137, issue.5, pp.873-86, 2009.

T. R. Peterson, S. Shomit, T. E. Sengupta, A. E. Harris, S. A. Carmack et al., « MTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP Pathway, Cell, vol.146, issue.3, pp.408-428, 2011.

K. N. Pollizzi, H. Chirag, I. Patel, M. Sun, A. T. Oh et al., MTORC1 and MTORC2 Selectively Regulate CD8 + T Cell Differentiation, vol.125, pp.2090-2108, 2015.

C. J. Potter, G. Laura, . Pedraza, . Et-tian, and . Xu, Akt Regulates Growth by Directly Phosphorylating Tsc2 », Nature Cell Biology, vol.4, issue.9, pp.658-65, 2002.

C. Procaccini, V. D. Rosa, M. Galgani, L. Abanni, G. Calì et al., « An Oscillatory Switch in MTOR Kinase Activity Sets Regulatory T Cell Responsiveness, Immunity, vol.33, issue.6, pp.929-970, 2010.

X. Qian, K. Wang, X. Wang, L. Song-guo-zheng, and . Lu, « Generation of Human Regulatory T Cells de Novo with Suppressive Function Prevent Xenogeneic Graft versus Host Disease, International Immunopharmacology, vol.11, issue.5, pp.630-667, 2011.

Z. Qin, T. Et, and . Blankenstein, « CD4+ T Cell--Mediated Tumor Rejection Involves Inhibition of Angiogenesis That Is Dependent on IFN Gamma Receptor Expression by Nonhematopoietic Cells, Immunity, vol.12, issue.6, pp.677-86, 2000.

R. R. Rao, Q. Li, M. R. Gubbels, and . Bupp, et Protul A. Shrikant. 2012. « Transcription Factor Foxo1 Represses T-Bet-Mediated Effector Functions and Promotes Memory CD8(+) T Cell Differentiation, vol.36, pp.374-87

R. R. Rao, Q. Li, K. Odunsi, A. Et-protul, and . Shrikant, « The MTOR Kinase Determines Effector versus Memory CD8+ T Cell Fate by Regulating the Expression of Transcription Factors T-Bet and Eomesodermin, Immunity, vol.32, issue.1, pp.67-78, 2010.

B. Raught, F. Peiretti, A. Gingras, M. Livingstone, D. Shahbazian et al., « Phosphorylation of Eucaryotic Translation Initiation Factor 4B Ser422 Is Modulated by S6 Kinases, The EMBO Journal, vol.23, issue.8, pp.1761-69, 2004.

A. Ray, B. Khong, H. T. Et, and . Khong, « A Case Report of Pneumocystis Jiroveci Pneumonia in a Patient with Metastatic Breast Cancer, Anticancer Research, vol.36, issue.12, pp.6673-76, 2016.

E. Raymond, J. Alexandre, S. Faivre, K. Vera, E. Materman et al., « Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel MTOR Inhibitor, in Patients with Cancer, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.22, issue.12, pp.2336-2383, 2004.

J. P. Ridge, F. D. Rosa, and E. P. Matzinger, « A Conditioned Dendritic Cell Can Be a Temporal Bridge between a CD4+ T-Helper and a T-Killer Cell », Nature, vol.393, issue.6684, pp.474-78, 1998.

P. C. Rodriguez, S. Marc, C. Ernstoff, M. Hernandez, J. Atkins et al., « Arginase I-Producing Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Are a Subpopulation of Activated Granulocytes », Cancer Research, vol.69, issue.4, pp.1553-60, 2009.

V. S. Rodrik-outmezguine, M. Okaniwa, Z. Yao, C. J. Novotny, C. Mcwhirter et al., « Overcoming MTOR Resistance Mutations with a New-Generation MTOR Inhibitor, Nature, vol.534, issue.7606, pp.272-76, 2016.

S. A. Rosenberg, « IL-2: The First Effective Immunotherapy for Human Cancer », Journal of Immunology, vol.192, issue.12, pp.5451-58, 1950.

S. A. Rosenberg, C. James, R. M. Yang, U. S. Sherry, M. S. Kammula et al., Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy, vol.17, pp.4550-57, 2011.

. Rubio-viqueira, M. Belen, and . Hidalgo, « Targeting MTOR for Cancer Treatment, Advances in Experimental Medicine and Biology, vol.587, pp.309-336, 2006.

D. M. Sabatini, H. Erdjument-bromage, M. Lui, P. Tempst, and S. H. Snyder, « RAFT1: A Mammalian Protein That Binds to FKBP12 in a Rapamycin-Dependent Fashion and Is Homologous to Yeast TORs, Cell, vol.78, issue.1, pp.35-43, 1994.

M. Sabbatini, G. Ruggiero, A. T. Palatucci, V. Rubino, S. Federico et al., Oscillatory MTOR Inhibition and Treg Increase in Kidney Transplantation, vol.182, pp.230-270, 2015.

C. J. Sabers, M. M. Martin, G. J. Brunn, J. M. Williams, F. J. Dumont et al., « Isolation of a Protein Target of the FKBP12-Rapamycin Complex in Mammalian Cells, The Journal of Biological Chemistry, vol.270, issue.2, pp.815-837, 1995.

S. Sakaguchi, N. Sakaguchi, M. Asano, M. Itoh, and M. Toda, « Immunologic SelfTolerance Maintained by Activated T Cells Expressing IL-2 Receptor Alpha-Chains (CD25), Journal of Immunology, vol.155, issue.3, pp.1151-64, 1950.

A. Sakata, K. Kuwahara, T. Ohmura, S. Inui, and N. Sakaguchi, « Involvement of a Rapamycin-Sensitive Pathway in CD40-Mediated Activation of Murine B Cells in Vitro, Immunology Letters, vol.68, issue.2-3, pp.301-310, 1999.

F. Sallusto, D. Lenig, R. Förster, M. Lipp, and A. Lanzavecchia, Two Subsets of Memory T Lymphocytes with Distinct Homing Potentials and Effector Functions, vol.401, pp.708-720, 1999.

M. Salvadori, Antineoplastic Effects of Mammalian Target of Rapamycine Inhibitors, World Journal of Transplantation, vol.2, issue.5, pp.74-83, 2012.

. Sancak, T. R. Yasemin, Y. D. Peterson, R. A. Shaul, C. C. Lindquist et al., The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to MTORC1 ». Science, vol.320, pp.1496-1501, 2008.

D. D. Sarbassov, M. Siraj, D. Ali, D. A. Kim, R. R. Guertin et al., « Rictor, a Novel Binding Partner of MTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway That Regulates the Cytoskeleton, Current Biology: CB, vol.14, issue.14, pp.1296-1302, 2004.

D. D. Sarbassov, A. David, S. M. Guertin, D. M. Ali, and . Sabatini, « Phosphorylation and Regulation of Akt/PKB by the Rictor-MTOR Complex, Science, vol.307, issue.5712, pp.1098-1101, 2005.

. Sathaliyawala, W. E. Taheri, M. O'gorman, M. Greter, . Bogunovic et al.,

, « Mammalian Target of Rapamycin Controls Dendritic Cell Development Downstream of Flt3 Ligand Signaling, vol.33, pp.597-606

S. Sauer, L. Bruno, A. Hertweck, D. Finlay, M. Leleu et al., « T Cell Receptor Signaling Controls Foxp3 Expression via PI3K, Akt, and MTOR, Proceedings of the National Academy of Sciences of the United States of America, vol.105, pp.7797-7802, 2008.

C. Sautès-fridman, M. Lawand, N. A. Giraldo, H. Kaplon, C. Germain et al., « Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention, Frontiers in Immunology, vol.7, p.407, 2016.

F. P. Schena, D. Michael, J. Pascoe, M. Alberu, R. Del-carmen-rial et al., « Conversion from Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results from the CONVERT Trial, Transplantation, vol.87, issue.2, pp.233-275, 2009.

U. Schenk, M. Frascoli, M. Proietti, R. Geffers, E. Traggiai et al., « ATP Inhibits the Generation and Function of Regulatory T Cells through the Activation of Purinergic P2X Receptors, Science Signaling, vol.4, issue.162, p.12, 2011.

T. H. Schreiber, D. Wolf, M. Bodero, E. Et, and . Podack, « Tumor Antigen Specific ITreg Accumulate in the Tumor Microenvironment and Suppress Therapeutic Vaccination, Oncoimmunology, vol.1, issue.5, pp.642-690, 2012.

E. S. Schultz, B. Lethé, C. L. Cambiaso, J. Van-snick, P. Chaux et al., « A MAGE-A3 Peptide Presented by HLA-DP4 Is Recognized on Tumor Cells by CD4+ Cytolytic T Lymphocytes, vol.60, pp.6272-75, 2000.

P. Serafini, K. Meckel, M. Kelso, K. Noonan, J. Califano et al., , p.5, 2006.

, Inhibition Augments Endogenous Antitumor Immunity by Reducing Myeloid-Derived Suppressor Cell Function, The Journal of Experimental Medicine, vol.203, issue.12, pp.2691-2702

S. Göksu, S. Sema, . Bilal, and . Et-hasan-?enol-co?kun, « Hepatitis B Reactivation Related to Everolimus, World Journal of Hepatology, vol.5, issue.1, pp.43-45, 2013.

K. A. Shafer-weaver, J. Michael, K. Anderson, A. Stagliano, N. M. Malyguine et al., « Cutting Edge: Tumor-Specific CD8+ T Cells Infiltrating Prostatic Tumors Are Induced to Become Suppressor Cells », Journal of Immunology, vol.183, issue.8, pp.4848-52, 1950.

V. Shankaran, H. Ikeda, A. T. Bruce, J. M. White, P. E. Swanson et al., « IFNgamma and Lymphocytes Prevent Primary Tumour Development and Shape Tumour Immunogenicity », Nature, vol.410, issue.6832, pp.1107-1118, 2001.

. Shin, J. Ho-jin, D. B. Baker, A. T. Leveson-gower, E. I. Smith et al., « Rapamycin and IL-2 Reduce Lethal Acute Graft-versus-Host Disease Associated with Increased Expansion of Donor Type CD4+CD25+Foxp3+ Regulatory T Cells, Blood, vol.118, issue.8, pp.2342-50, 2011.

L. V. Sinclair, D. Finlay, C. Feijoo, G. H. Cornish, A. Gray et al., Hergen Spits, et Doreen A. Cantrell. 2008. « Phosphatidylinositol-3-OH Kinase and Nutrient-Sensing MTOR Pathways Control T Lymphocyte Trafficking », Nature Immunology, vol.9, issue.5, pp.513-534

M. Slegtenhorst, R. Van, C. Hoogt, M. Hermans, B. Nellist et al., Identification of the Tuberous Sclerosis Gene TSC1 on Chromosome 9q34 ». Science, vol.277, pp.805-813, 1997.

G. Stallone, A. Schena, B. Infante, S. D. Paolo, A. Loverre et al., « Sirolimus for Kaposi's Sarcoma in Renal-Transplant Recipients, The New England Journal of Medicine, vol.352, issue.13, pp.1317-1340, 2005.

D. L. Stanculeanu, A. Lazescu, D. D. Zob, R. Bunghez, R. Anghel et al., « Metastatic Clear Cell Renal Carcinoma - an Unusual Response to Temsirolimus in Second Line Therapy, Journal of Medicine and Life, vol.9, issue.2, pp.193-98, 2016.

K. Steinbrink, M. Wölfl, H. Jonuleit, J. Knop, and A. H. Enk, « Induction of Tolerance by IL-10-Treated Dendritic Cells », Journal of Immunology, vol.159, issue.10, pp.4772-80, 1950.

L. Strauss, T. L. Whiteside, A. Knights, and C. Bergmann, « Selective Survival of Naturally Occurring Human CD4+CD25+Foxp3+ Regulatory T Cells Cultured with Rapamycin », Journal of Immunology, vol.178, issue.1, pp.320-349, 1950.

C. D. Surh, J. Et, and . Sprent, Homeostasis of Naive and Memory T Cells, vol.29, pp.848-62, 2008.

J. Tabernero, F. Rojo, E. Calvo, H. Burris, I. Judson et al., « Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway with Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients with Advanced Solid Tumors, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.26, issue.10, pp.1603-1613, 2008.

A. Takano, I. Usui, T. Haruta, J. Kawahara, T. Uno et al., « Mammalian Target of Rapamycin Pathway Regulates Insulin Signaling via Subcellular Redistribution of Insulin Receptor Substrate 1 and Integrates Nutritional Signals and Metabolic Signals of Insulin, Molecular and Cellular Biology, vol.21, issue.15, pp.5050-62, 2001.

. Tamás, S. A. Peter, R. G. Hawley, K. J. Clarke, K. Mustard et al., « Regulation of the Energy Sensor AMP-Activated Protein Kinase by Antigen Receptor and Ca2+ in T Lymphocytes, The Journal of Experimental Medicine, vol.203, issue.7, 2006.

A. J. Templeton, V. Dutoit, R. Cathomas, C. Rothermundt, D. Bärtschi et al., « Phase 2 Trial of Single-Agent Everolimus in Chemotherapy-Naive Patients with Castration-Resistant Prostate Cancer (SAKK 08/08) », European Urology, vol.64, issue.1, pp.150-58, 2013.

A. Thiery-vuillemin, G. Mouillet, T. Nguyen-tan-hon, P. Montcuquet, T. Maurina et al., « Impact of Everolimus Blood Concentration on Its Anti-Cancer Activity in Patients with Metastatic Renal Cell Carcinoma, Cancer Chemotherapy and Pharmacology, vol.73, issue.5, pp.999-1007, 2014.

A. Thiery-vuillemin, C. Laheurte, L. Mansi, B. Royer, X. Pivot et al., « Immunomodulatory Effects of Everolimus in a Long Responsive Patient with Metastatic Renal Cell Carcinoma », Journal of Immunotherapy, vol.37, issue.1, pp.51-54, 1997.

Y. Tone, K. Furuuchi, Y. Kojima, M. L. Tykocinski, M. I. Greene et al., « Smad3 and NFAT Cooperate to Induce Foxp3 Expression through Its Enhancer », Nature Immunology, vol.9, issue.2, pp.194-202, 2008.

A. P. Turner, V. O. Shaffer, K. Araki, C. Martens, P. L. Turner et al., Sirolimus Enhances the Magnitude and Quality of Viral-Specific CD8+ T-Cell Responses to Vaccinia Virus Vaccination in Rhesus Macaques, vol.11, pp.613-631, 2011.

L. Vallotton, K. Hadaya, J. Venetz, L. H. Buehler, D. Ciuffreda et al.,

, « Monitoring of CD4+CD25highIL-7R?high Activated T Cells in Kidney Transplant Recipients, vol.6, pp.2025-2058

T. Vandamme, M. Beyens, K. Op-de-beeck, F. Dogan, P. M. Van-koetsveld et al., « Long-Term Acquired Everolimus Resistance in Pancreatic Neuroendocrine Tumours Can Be Overcome with Novel PI3K-AKT-MTOR Inhibitors, British Journal of Cancer, vol.114, issue.6, pp.650-58, 2016.

V. Haar, S. Emilie, S. Lee, T. J. Bandhakavi, D. Griffin et al., « Insulin Signalling to MTOR Mediated by the Akt/PKB Substrate PRAS40 », Nature Cell Biology, vol.9, issue.3, pp.316-339, 2007.

M. D. Vesely, H. Michael, R. D. Kershaw, M. J. Schreiber, and . Smyth, Natural Innate and Adaptive Immunity to Cancer, vol.29, pp.235-71, 2011.

C. Vézina, A. Kudelski, and S. N. Sehgal, « Rapamycin (AY-22,989), a New Antifungal Antibiotic. I. Taxonomy of the Producing Streptomycete and Isolation of the Active Principle, The Journal of Antibiotics, vol.28, issue.10, pp.721-747, 1975.

D. A. Vignali, W. Lauren, . Collison, C. J. Et, and . Workman, « How Regulatory T Cells Work », Nature Reviews. Immunology, vol.8, issue.7, pp.523-555, 2008.

M. H. Voss, D. Chen, M. Marker, A. A. Hakimi, C. Lee et al., « Circulating Biomarkers and Outcome from a Randomised Phase II Trial of Sunitinib vs Everolimus for Patients with Metastatic Renal Cell Carcinoma, British Journal of Cancer, vol.114, issue.6, pp.642-691, 2016.

M. Voss, D. Henner, M. Chen, J. Marker, P. Xu et al., « Tumor genomic analysis for 128 renal cell carcinoma (RCC) patients receiving first-line everolimus: Correlation between outcome and mutations status in MTOR, TSC1, and TSC2, Journal of Clinical Oncology, vol.35, pp.484-484, 2017.

B. T. Wang, S. Gregory, A. J. Ducker, R. Barczak, D. J. Barbeau et al., « The Mammalian Target of Rapamycin Regulates Cholesterol Biosynthetic Gene Expression and Exhibits a Rapamycin-Resistant Transcriptional Profile, Proceedings of the National Academy of Sciences of the United States of America, vol.108, pp.15201-15207, 2011.

C. Wang, R. Jing, L. Kenefeck, K. Wardzinski, C. Attridge et al., « Cutting Edge: Cell-Extrinsic Immune Regulation by CTLA-4 Expressed on Conventional T Cells », Journal of Immunology, vol.189, issue.3, pp.1118-1140, 1950.

. Wang, T. E. Lifu, R. A. Harris, J. C. Roth, and . Lawrence, PRAS40 Regulates MTORC1 Kinase Activity by Functioning as a Direct Inhibitor of Substrate Binding, vol.282, pp.20036-20080, 2007.

Y. Wang, X. Wang, J. R. Subjeck, P. A. Shrikant, and H. L. Kim, « Temsirolimus, an MTOR Inhibitor, Enhances Anti-Tumour Effects of Heat Shock Protein Cancer Vaccines, British Journal of Cancer, vol.104, issue.4, pp.643-52, 2011.

O. Warburg, « THE CHEMICAL CONSTITUTION OF RESPIRATION FERMENT, Science, vol.68, pp.437-480, 1767.

E. Wherry, V. John, T. C. Teichgräber, D. Becker, S. M. Masopust et al., et Rafi Ahmed. 2003. « Lineage Relationship and Protective Immunity of Memory CD8 T Cell Subsets, vol.4, pp.225-259

M. A. Williams, M. J. Et, and . Bevan, Effector and Memory CTL Differentiation, vol.25, pp.171-92, 2007.

A. A. Wu, V. Drake, H. Huang, and S. Chiu, et Lei Zheng. 2015. « Reprogramming the Tumor Microenvironment: Tumor-Induced Immunosuppressive Factors Paralyze T Cells ». Oncoimmunology, vol.4, p.1016700

Q. Wu, K. Kiguchi, T. Kawamoto, T. Ajiki, J. Traag et al., Therapeutic Effect of Rapamycin on Gallbladder Cancer in a Transgenic Mouse Model, vol.67, pp.3794-3800, 2007.

D. Xie, J. Wu, Y. Lou, and X. Zhong, « Tumor Suppressor TSC1 Is Critical for T-Cell Anergy, Proceedings of the National Academy of Sciences of the United States of America, vol.109, pp.14152-57, 2012.

J. Xie, X. Wang, and C. G. Proud, MTOR Inhibitors in Cancer Therapy ». F1000Research, vol.5, p.2078, 2016.

L. Xu, Q. Huang, H. Wang, Y. Hao, Q. Bai et al., The Kinase MTORC1 Promotes the Generation and Suppressive Function of Follicular Regulatory T Cells, vol.47, pp.538-551, 2017.

X. Xu, L. Ye, and K. Araki, et Rafi Ahmed. 2012. « MTOR, Linking Metabolism and Immunity, vol.24, pp.429-464

K. Yang and H. Chi, MTOR and Metabolic Pathways in T Cell Quiescence and Functional Activation, vol.24, pp.421-449, 2012.

K. Yang, G. Neale, D. R. Green, W. He, H. Et et al., « The Tumor Suppressor Tsc1 Enforces Quiescence of Naive T Cells to Promote Immune Homeostasis and Function », Nature Immunology, vol.12, issue.9, pp.888-97, 2011.

J. Youn, S. Nagaraj, M. Collazo, D. I. Et, and . Gabrilovich, « Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice », Journal of Immunology, vol.181, issue.8, pp.5791-5802, 1950.

. Yu, . Cheng-rong, M. Rashid, S. Mahdi, B. P. Ebong et al., « Suppressor of Cytokine Signaling 3 Regulates Proliferation and Activation of T-Helper Cells, The Journal of Biological Chemistry, vol.278, issue.32, pp.29752-59, 2003.

T. L. Yuan and L. C. Cantley, « PI3K Pathway Alterations in Cancer: Variations on a Theme, Oncogene, vol.27, issue.41, pp.5497-5510, 2008.

A. H. Zea, C. Paulo, M. B. Rodriguez, C. Atkins, S. Hernandez et al., « Arginase-Producing Myeloid Suppressor Cells in Renal Cell Carcinoma Patients: A Mechanism of Tumor Evasion », Cancer Research, vol.65, issue.8, pp.3044-3092, 2005.

. Zeiser, D. B. Robert, E. A. Leveson-gower, N. Zambricki, A. Kambham et al., Differential Impact of Mammalian Target of Rapamycin Inhibition on CD4+CD25+Foxp3+ Regulatory T Cells Compared with Conventional CD4+ T Cells, vol.111, pp.453-62, 2008.

. Zeng, . Hu, H. Et, and . Chi, MTOR Signaling in the Differentiation and Function of Regulatory and Effector T Cells, vol.46, pp.103-114, 2017.

. Zeng, K. Hu, C. Yang, G. Cloer, P. Neale et al., « MTORC1 Couples Immune Signals and Metabolic Programming to Establish T(Reg)-Cell Function », Nature, vol.499, issue.7459, pp.485-90, 2013.

C. Zhang, S. Wang, J. Li, W. Zhang, L. Zheng et al., Tongyu Zhu, et Ruiming Rong. 2017. « The MTOR Signal Regulates Myeloid-Derived Suppressor Cells Differentiation and Immunosuppressive Function in Acute Kidney Injury, Cell Death & Disease, vol.8, issue.3, p.2695

H. Zhang, N. Bajraszewski, E. Wu, H. Wang, A. P. Moseman et al., « PDGFRs Are Critical for PI3K/Akt Activation and Negatively Regulated by MTOR, The Journal of Clinical Investigation, vol.117, issue.3, pp.730-768, 2007.

. Zhang, J. R. Lin, D. Conejo-garcia, P. A. Katsaros, M. Gimotty et al., Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer, vol.348, pp.203-216, 2003.

W. Zhang, D. Zhang, M. Shen, Y. Liu, Y. Tian et al., « Combined Administration of a Mutant TGFBeta1/Fc and Rapamycin Promotes Induction of Regulatory T Cells and Islet Allograft Tolerance », Journal of Immunology, vol.185, issue.8, pp.4750-59, 1950.

J. Zhu, H. Yamane, W. E. Et, and . Paul, Differentiation of Effector CD4 T Cell Populations (*), vol.28, pp.445-89, 2010.

V. Zinzalla, D. Stracka, W. Oppliger, M. N. Et, and . Hall, Activation of MTORC2 by Association with the Ribosome, vol.144, pp.757-68, 2011.

L. Zitvogel, L. Galluzzi, M. J. Smyth, and G. Kroemer, Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance, vol.39, pp.74-88, 2013.

L. Zitvogel, L. Galluzzi, M. J. Smyth, and G. Kroemer, Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance, vol.39, pp.74-88, 2013.